【レポートの概要（一部）】
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chemotherapy Induced Neutropenia Overview 10
Therapeutics Development 11
Pipeline Products for Chemotherapy Induced Neutropenia – Overview 11
Pipeline Products for Chemotherapy Induced Neutropenia – Comparative Analysis 12
Chemotherapy Induced Neutropenia – Therapeutics under Development by Companies 13
Chemotherapy Induced Neutropenia – Therapeutics under Investigation by Universities/Institutes 16
Chemotherapy Induced Neutropenia – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Chemotherapy Induced Neutropenia – Products under Development by Companies 21
Chemotherapy Induced Neutropenia – Products under Investigation by Universities/Institutes 24
Chemotherapy Induced Neutropenia – Companies Involved in Therapeutics Development 25
Bio-Ker s.r.l 25
Biogenomics Limited 26
Bolder Biotechnology, Inc. 27
Cellerant Therapeutics, Inc. 28
Coherus BioSciences, Inc. 29
Dong-A Socio Group 30
Generon (Shanghai) Corporation Ltd. 31
Hanmi Pharmaceuticals, Co. Ltd. 32
Io Therapeutics, Inc. 33
Mycenax Biotech Inc. 34
Myelo Therapeutics GmbH 35
Octapharma AG 36
PharmaEssentia Corporation 37
Reliance Life Sciences Pvt. Ltd. 38
Richter Gedeon Nyrt. 39
Sandoz Inc. 40
Sandoz International GmbH 41
Teva Pharmaceutical Industries Limited 42
UAB Profarma 43
USV Limited 44
Welichem Biotech Inc. 45
XBiotech USA, Inc. 46
Chemotherapy Induced Neutropenia – Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Target 48
Assessment by Mechanism of Action 50
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
balugrastim – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
BBT-007 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BBT-015 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
BBT-018 – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BK-0026 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Cell Therapy for Chemotherapy Induced Neutropenia – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
F-627 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
filgrastim – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
filgrastim – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
filgrastim – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
filgrastim – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
filgrastim – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
filgrastim – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
filgrastim – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
filgrastim (recombinant) – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
GW-003 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
HM-10460A – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
IRX-4310 – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
lipegfilgrastim – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Myelo-001 – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
pegfilgrastim – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
pegfilgrastim – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
pegfilgrastim – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
pegfilgrastim – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
pegfilgrastim – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
pegfilgrastim – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
pegfilgrastim – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
pegfilgrastim – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Recombinant Protein for Chemotherapy Induced Neutropenia – Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
romyelocel-L – Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
TXA-302 – Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
WBI-2100 – Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Chemotherapy Induced Neutropenia – Recent Pipeline Updates 92
Chemotherapy Induced Neutropenia – Dormant Projects 98
Chemotherapy Induced Neutropenia – Discontinued Products 100
Chemotherapy Induced Neutropenia – Product Development Milestones 101
Featured News & Press Releases 101
Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco 101
Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm 102
May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 – A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia 103
Mar 25, 2014: Sandoz receives approval for biosimilar filgrastim in Japan 103
Nov 18, 2013: Teva announces Launch of LONQUEX Injection 104
Jul 22, 2013: Zarzio overtakes Neupogen and Granocyte to become most prescribed daily G-CSF in Europe 105
Jun 03, 2013: Teva’s Lonquex Receives Positive Opinion From CHMP For Reduction Of Chemotherapy-induced Neutropenia 105
Apr 25, 2013: Sandoz Files For Marketing Authorization Of Biosimilar Filgrastim In Japan 106
Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia 106
Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China 107
Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 109
Disclaimer 109
【レポート販売概要】
■ タイトル：化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)の治療薬パイプライン動向（2015年上半期版）■ 英文：Chemotherapy Induced Neutropenia - Pipeline Review, H1 2015
■ 発行日：2015年1月22日
■ 調査会社：Global Markets Direct
■ 商品コード：GMDHC6036IDB
■ 調査対象地域：グローバル
- 医療レポート：Postherpetic Neuralgia-疫学予測（～2022）EpiCast Report: Postherpetic Neuralgia - Epidemiology Forecast to 2022 Summary Postherpetic Neuralgia (PHN) is one of the most common complications of herpes zoster infection in elderly persons ages 60 years and older, worldwide. The main symptom of PHN is severe pain and allodynia (pain that results from a non-injurious stimulus to the skin). PHN is associated with a significant loss of activity …
- バーコードリーダーの世界市場2015-2019About Barcode Scanners A barcode is a systematic representation of data depicted in parallel lines with varied spacing and width. Barcode scanner is an electronic device used to read the information contained in barcode. It works by converting the light energy into electrical energy. TechNavio's analysts forecast the Global Barcode Scanner market to grow at a CAGR of 4.05 percent over the period 2 …
- 双極性障害市場：カナダの治療薬市場Bipolar Disorder - Canada Drug Forecast and Market Analysis to 2024 Summary Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely g …
- Kodiak Oil & Gas Corp.：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013Kodiak Oil & Gas Corp. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Kodiak Oil & Gas Corp. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential sour …
- 手術用器具の世界市場2018-2022About Global Surgical Instruments Surgical instruments are widely used in surgeries for making incisions, grasping the skin or tissues, coagulation of blood vessels, providing access to the site of operation, and closing the wound. Technavio’s analysts forecast the Global Surgical Instruments Market to grow at a CAGR of 6.22% during the period 2018-2022. Covered in this report The report covers th …
- クラウドアプリケーションのマーケットプレイス（Cloud Application Marketplace 2013 – 2018）There are thousands of cloud applications in the market that are offered by hundreds of vendors. To gain a competitive advantage in the cloud applications market, companies are collaborating in the development and/or delivery of solutions that solve enterprise problems, optimize operations, improve customer relations and services delivery. Many of these solutions rely upon open APIs for access to …
- アルコール試験装置の世界市場2016-2020：飲酒検知器（ブレサライザー）、アルコール検知用尿検査装置、アルコール検知用唾液検査装置About Alcohol Testing Equipment Alcohol testing equipment is used to determine the blood alcohol concentration from a test sample of a person. It is largely used by law enforcement agencies and hospitals worldwide. Alcohol detection breath analyzers/breathalyzers, urine testing kits, and saliva test equipment are widely used for the purpose of detecting alcohol concentration in the blood. The brea …
- クラウド基盤給与計算ソフトの世界市場2016-2020About Cloud-Based Payroll Software In HR, the payroll department is critical as employees are sensitive to payroll errors and irregularities. The key task of the payroll department is to ensure that all the employees are paid accurately and appropriately after the correct deductions. In addition, with the use of the payroll software, the HR team can track the number of hours each employee has work …
- 世界の生体外毒性/毒性テスト市場動向及び予測（～2018）Attributed to the support offered by the European government, the in vitro toxicology testing market in Europe was the largest in 2013 and is expected to hold the same stance by 2018 There has been a substantial rise in the costs to develop a new pharmaceutical product in recent years. This is specially observed when a new compound enters animal testing and clinical trials. The use of animals in e …
- Wrangler West Energy Corp.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Wrangler West Energy Corp. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Wrangler West Energy Corp. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essent …
- Von Willebrand Disease：グローバル臨床試験レビューH2, 2013Von Willebrand Disease Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Von Willebrand Disease Global Clinical Trials Review, H2, 2013" provides data on the Von Willebrand Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Von Willebrand Disease. It includes an overview of the trial numbers and …
- カミソリ及びカミソリ用刃市場（～2019）：世界市場The expansion of the global razor and razor blade industry is forecast to reach 1.3% p.a. in the coming years. Between 2008 and 2014 the market increased with an average annual growth of 4.0%. Currently, razors account for 55.2% of the global demand while the remaining market share is divided between safety razor blades (40.2%) and parts of non-electric razors (4.6%). China, Germany, Japan, Poland …
- テトロドトキシンの世界市場Tetrodotoxin (CAS 4368-28-9) Market Research Report 2013 presents comprehensive data on Tetrodotoxin markets globally and regionally (Europe, Asia, North America etc.) The Tetrodotoxin (CAS 4368-28-9) Market Research Report 2013 includes Tetrodotoxin description, covers its application areas and related patterns. It overviews Tetrodotoxin market, names Tetrodotoxin producers and indicates its supp …
- ライム病検査の世界市場2015The report presents a detailed analysis of the Lyme disease diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Lyme disease definition, epidemiology and etiology are reviewed. The report provides the 5- and 10-year test volume and sales forecasts by country for the following market segments: - Hospitals …
- 水路測量装置の世界市場：ポジショニングシステム、水中音響システム、海洋地球物理学システム、海洋学装置The hydrographic survey equipment market is projected to grow from USD 2.77 Billion in 2016 to USD 3.62 Billion by 2021, at a CAGR of 5.43% during the forecast period. Various factors, such as rising maritime trade, increase in demand for accurate nautical charts, and coastal zone management & development in the market for hydrographic survey equipment are expected to drive the hydrographic survey …
